ABLYNX SELECTS A NOVEL PRE-CLINICAL DEVELOPMENT CANDIDATE FOR ADMINISTRATION VIA PULMONARY DELIVERY

(Thomson Reuters ONE) -


GHENT, Belgium, 26 March 2010 - Ablynx [Euronext Brussels: ABLX] announced today
that it has advanced ALX-0171, a new Nanobody®-based therapeutic programme, into
pre-clinical development for the treatment of respiratory synctial virus (RSV)
infections. ALX-0171 is a Nanobody product which binds to RSV and neutralizes
the virus. The Nanobody will be administered via the lungs and based on the in
vivo data it has the potential to be effective both in the prevention of
infection as well as in treatment once infection has occurred.

This is Ablynx's first Nanobody pre-clinical development candidate to be
delivered through a route other than injection. Like many Nanobodies, ALX-0171
is very stable with a low propensity to aggregate making it suitable for
inhalation. It can also be manufactured at relatively low cost in microbial
systems.

"Ablynx's anti-RSV Nanobody potentially has a clearly differentiated product
profile compared with other options currently available for RSV. We expect to
conveniently deliver ALX-0171 via the lungs directly to the site of potential
disease to provide prophylactic protection, as well as therapeutic treatment
which we don't believe can be offered for this infectious agent by any other
marketed drugs today. We also believe ALX-0171 will have a significantly lower
cost of goods compared to other biologics currently used in this indication. We
are very pleased to illustrate the power of our Nanobody product engine with
this announcement of our second pre-clinical candidate nomination in 2010.
Earlier this year we nominated ALX-0651, an anti-CXCR4 Nanobody for stem cell
mobilization, for preclinical development", commented Dr. Edwin Moses, Chief
Executive Officer and Chairman of Ablynx.


-ends-

For more information, please contact Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e:edwin.moses(at)ablynx.com

Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e:eva-lotta.allan(at)ablynx.com



[HUG#1397942]





Complete version of the press release: http://hugin.info/137912/R/1397942/353717.pdf

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 26.03.2010 - 08:00 Uhr
Sprache: Deutsch
News-ID 18124
Anzahl Zeichen: 0

contact information:
Town:

Ghent

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 242 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"ABLYNX SELECTS A NOVEL PRE-CLINICAL DEVELOPMENT CANDIDATE FOR ADMINISTRATION VIA PULMONARY DELIVERY"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regar ...

GHENT, BELGIUM -- (Marketwired) -- 08/27/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to tr ...

Ablynx Announces Half-Year Results for 2013 ...

GHENT, BELGIUM -- (Marketwired) -- 08/21/13 -- (EURONEXT BRUSSELS: ABLX) today announced its results for the six-month period ending 30 June 2013, which have been prepared in accordance with the IAS 34 "Interim Financial Reporting" as adop ...

Ablynx Announces Warrant Exercise ...

GHENT, BELGIUM -- (Marketwired) -- 07/23/13 -- (EURONEXT BRUSSELS: ABLX) today announced, in conformity with Title II of the Law of 2 May 2007 and the Royal Decree of 14 February 2008, that an additional 273,913 common shares have been issued by the ...

Alle Meldungen von Ablynx